Advertisement

Topics

Partnerships, Licensing, Investments and MA Deals and Trends in Pharmaceuticals Q1 2017 [Report Updated: 03072017] Prices from USD $1500

09:50 EDT 2 Aug 2017 | BioPortfolio Report Blog

Partnerships, Licensing, Investments and MA Deals and Trends in Pharmaceuticals Q1 2017

Summary

GlobalData's "Partnerships, Licensing, Investments and MA Deals and Trends in Pharmaceuticals Q1 2017", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions MAs and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, MAs, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary inhouse Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and an increase in deal values in Q1 2017 with 1,142 deals worth USD95.5 billion, as compared 1,165 worth USD91.4 billion in Q1 2016. On a quarteronquarter basis, the number of deals and deal values increased in Q1 2017, when compared to 1,082 deals worth USD84.3 billion in Q4 2016. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD731m in Q1 2017, as compared USD1.3 billion in Q1 2016. On a quarteronquarter basis, the upfront payments reported a decrease in Q1 2017, when compared to USD1 billion in Q4 2016. Deals in oncology therapeutics market registered an increase with 421 deals in Q1 2017, compared to 356 deals in Q4 2016.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.
Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
Analysis of partnerships, licensing, MAs, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and MAs.
Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
Analysis of partnership and licensing deals based on clinical stage of development of products.
Summary of the pharmaceutical deals globally in the five quarters.
Information on the top deals happened in the pharmaceutical industry.
Geographies covered include North America, Europe, Asia Pacific, South Central America, and the Middle East Africa.
League tables of financial advisors in MAs and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.
Find out the major deal performing segments for investments in your industry.
Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
Identify companies that are aggressively looking to raise capital in the market
Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
Identify growth segments and opportunities in each region within the industry.
Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Original Article: Partnerships, Licensing, Investments and MA Deals and Trends in Pharmaceuticals Q1 2017 [Report Updated: 03072017] Prices from USD $1500

NEXT ARTICLE

More From BioPortfolio on "Partnerships, Licensing, Investments and MA Deals and Trends in Pharmaceuticals Q1 2017 [Report Updated: 03072017] Prices from USD $1500"

Quick Search
Advertisement
 

Relevant Topics

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...